Loading viewer...
investor_presentation
Format: PDF investor_presentation
Aridis Pharmaceuticals presented its investment thesis for novel anti-infective therapies targeting lung infections. The presentation outlines the company's clinical development pipeline and addresses key risk factors associated with regulatory approval, clinical trial execution, and market commercialization in the competitive biopharmaceutical space.
investor_presentation
34 Pages
investor_presentation
24 Pages
KLA Corporation